Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
Fractyl Health, Inc. (Nasdaq: GUTS), a metabolic therapeutics company focusing on new approaches to treat obesity and Type 2 Diabetes, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. The company's Co-founder and CEO, Harith Rajagopalan, M.D., Ph.D., will engage in a fireside chat on Tuesday, October 1, 2024, at 9:00 a.m. EDT.
Interested parties can register in advance for the presentation webcast. Following the live session, a replay will be available on the Events page of the Investors section on Fractyl Health's website at https://ir.fractyl.com/. This presentation offers an opportunity for investors and interested individuals to gain insights into Fractyl Health's innovative approaches in metabolic therapeutics.
Fractyl Health, Inc. (Nasdaq: GUTS), un'azienda di terapie metaboliche che si concentra su nuovi approcci per trattare l'obesità e il diabete di tipo 2, ha annunciato la sua partecipazione alla 8ª Conferenza Annuale sui Farmaci Genetici di Chardan. Il co-fondatore e CEO dell'azienda, Harith Rajagopalan, M.D., Ph.D., parteciperà a una chiacchierata informale martedì 1 ottobre 2024, alle 9:00 a.m. EDT.
Le parti interessate possono registrarsi in anticipo per la diretta della presentazione. Dopo la sessione dal vivo, un replay sarà disponibile nella sezione Eventi del sito web di Fractyl Health all'indirizzo https://ir.fractyl.com/. Questa presentazione offre un'opportunità agli investitori e a coloro che sono interessati di ottenere approfondimenti sugli approcci innovativi di Fractyl Health nelle terapie metaboliche.
Fractyl Health, Inc. (Nasdaq: GUTS), una empresa de terapias metabólicas que se centra en nuevos enfoques para tratar la obesidad y la diabetes tipo 2, ha anunciado su participación en la 8ª Conferencia Anual de Medicamentos Genéticos de Chardan. El cofundador y CEO de la empresa, Harith Rajagopalan, M.D., Ph.D., participará en una charla informal el martes 1 de octubre de 2024, a las 9:00 a.m. EDT.
Las partes interesadas pueden registrarse con anticipación para la transmisión de la presentación. Después de la sesión en vivo, se podrá acceder a una repetición en la página de Eventos de la sección de Inversores en el sitio web de Fractyl Health en https://ir.fractyl.com/. Esta presentación ofrece una oportunidad para que los inversores y las personas interesadas obtengan información sobre los enfoques innovadores de Fractyl Health en las terapias metabólicas.
프랙틸 헬스, Inc. (Nasdaq: GUTS), 비만 및 제2형 당뇨병 치료를 위한 새로운 접근 방식을 목표로 하는 대사 치료 회사는 차르단의 제8회 연례 유전자 의약품 콘퍼런스에 참가한다고 발표했습니다. 회사의 공동 설립자이자 CEO인 하리쓰 라자고팔란, M.D., Ph.D.는 2024년 10월 1일 화요일 오전 9:00 EDT에 비공식 대담에 참여할 예정입니다.
관심 있는 분들은 발표 웹캐스트를 사전에 등록할 수 있습니다. 실시간 세션 후에는 프랙틸 헬스 웹사이트의 투자자 섹션 이벤트 페이지에서 재생이 가능할 것입니다 https://ir.fractyl.com/. 이 프레젠테이션은 투자자와 관심 있는 개인들이 프랙틸 헬스의 혁신적인 대사 치료 접근 방식을 이해할 수 있는 기회를 제공합니다.
Fractyl Health, Inc. (Nasdaq: GUTS), une entreprise de thérapies métaboliques axée sur de nouvelles approches pour traiter l'obésité et le diabète de type 2, a annoncé sa participation à la 8ème Conférence Annuelle sur les Médicaments Génétiques de Chardan. Le cofondateur et PDG de l'entreprise, Harith Rajagopalan, M.D., Ph.D., participera à une discussion informelle le mardi 1er octobre 2024, à 9h00 EDT.
Les parties intéressées peuvent s'inscrire à l'avance pour le webinaire de présentation. Après la session en direct, un rediffusion sera disponible sur la page Événements de la section Investisseurs du site web de Fractyl Health à l'adresse https://ir.fractyl.com/. Cette présentation offre une opportunité aux investisseurs et aux personnes intéressées d'obtenir des informations sur les approches innovantes de Fractyl Health en matière de thérapies métaboliques.
Fractyl Health, Inc. (Nasdaq: GUTS), ein Unternehmen für metabolische Therapien, das sich auf neue Ansätze zur Behandlung von Fettleibigkeit und Typ-2-Diabetes konzentriert, hat seine Teilnahme an Chardans 8. jährlicher Konferenz für genetische Medikamente bekannt gegeben. Der Mitgründer und CEO des Unternehmens, Harith Rajagopalan, M.D., Ph.D., wird diesen Dienstag, den 1. Oktober 2024, um 9:00 Uhr EDT an einem informellen Gespräch teilnehmen.
Interessierte Parteien können sich im Voraus für die Präsentationsübertragung anmelden. Nach der Live-Sitzung wird eine Wiederholung auf der Veranstaltungsseite im Investorenbereich der Website von Fractyl Health unter https://ir.fractyl.com/ verfügbar sein. Diese Präsentation bietet Anlegern und interessierten Personen die Möglichkeit, Einblicke in die innovativen Ansätze von Fractyl Health im Bereich der metabolischen Therapien zu gewinnen.
- None.
- None.
BURLINGTON, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D)), today announced that Harith Rajagopalan, M.D., Ph.D., Co-founder and Chief Executive Officer of Fractyl Health, will participate in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024, at 9:00 a.m. EDT.
To register in advance for the presentation webcast, sign up here.
A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.fractyl.com/.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com.
Contacts
Corporate Contact
Lisa Davidson, Chief Financial Officer
ir@fractyl.com, 781.902.8800
Media Contact
Jessica Cotrone, Corporate Communications
jcotrone@fractyl.com, 978.760.5622
Investor Contact
Stephen Jasper, Gilmartin Group
stephen@gilmartinir.com, 619.949.3681
FAQ
When is Fractyl Health (GUTS) presenting at Chardan's Genetic Medicines Conference?
Who will be representing Fractyl Health (GUTS) at the Chardan conference?
How can I watch Fractyl Health's (GUTS) presentation at the Chardan conference?
What is the focus of Fractyl Health's (GUTS) research?
